ストックスクリーナーアプリを入手
4.71
0.86%
0.04
前日終値:
$4.67
開ける：
$4.68
24時間の取引高:
1.57M
Relative Volume:
1.44
時価総額：
$905.85M
収益：
$12.99M
当期純損益:
$-74.39M
株価収益率:
-10.70
EPS:
-0.44
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
+6.56%
1か月 パフォーマンス:
-2.69%
6か月 パフォーマンス:
+31.56%
1年 パフォーマンス:
+32.30%
1日の値動き範囲:
$4.61
$4.81
1週間の範囲:
$4.38
$4.81
52週間の値動き範囲:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.71 | 898.15M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
A Look at Arbutus Biopharma Corp (ABUS) Shares in the Recent Past Indicates Growth - setenews.com
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation - TradingView
Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP - MarketBeat
The time has not yet come to remove your chips from the table: Arbutus Biopharma Corp (ABUS) - setenews.com
Why global investors buy Arbutus Biopharma Corporation (I9DN) stockWeekly Trend Summary & Community Supported Trade Ideas - Newser
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdown2025 Year in Review & Real-Time Stock Entry Alerts - Newser
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
Arbutus Biopharma (ABUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Arbutus Biopharma Corporation (I9DN) stock trades after earningsJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Why Arbutus Biopharma Corporation (I9DN) stock could outperform next yearJuly 2025 Short Interest & Safe Capital Allocation Plans - Newser
There is no way Arbutus Biopharma Corp (ABUS) can keep these numbers up - setenews.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
How Arbutus Biopharma Corporation (I9DN) stock reacts to new regulationsEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
A look into Arbutus Biopharma Corp (ABUS)’s deeper side - Setenews
Why Arbutus Biopharma Corporation stock is trending among retail tradersJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Arbutus Biopharma Corporation stock trend outlook and recovery pathQuarterly Market Summary & Daily Price Action Insights - newser.com
How Arbutus Biopharma Corporation (I9DN) stock compares with market leadersWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
How Arbutus Biopharma Corporation stock compares to growth peersMarket Risk Analysis & Fast Moving Trade Plans - newser.com
Arbutus Biopharma’s (ABUS) Buy Rating Reiterated at Chardan Capital - Defense World
Quantitative breakdown of Arbutus Biopharma Corporation recent move2025 Big Picture & Reliable Intraday Trade Plans - newser.com
Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital - MarketBeat
What indicators show strength in Arbutus Biopharma Corporation2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
What analysts say about Arbutus Biopharma Corporation I9DN stockBull Market Opportunities & Follow Top Performers in the Community - earlytimes.in
Arbutus Biopharma (ABUS) Receives Steady Buy Rating from Chardan Capital | ABUS Stock News - GuruFocus
Arbutus Biopharma Faces Losses And Legal Battles This Quarter - Finimize
Arbutus: Q3 Earnings Snapshot - New Haven Register
Arbutus Biopharma earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Arbutus Biopharma shares rise as imdusiran data shows promising results By Investing.com - Investing.com Canada
Arbutus Biopharma shares rise as imdusiran data shows promising results - Investing.com
Arbutus Biopharma earnings missed, revenue fell short of estimates - Investing.com
Arbutus (ABUS) Reports Q3 Results, Highlights Promising Imdusira - GuruFocus
Nothing is Better Than Arbutus Biopharma Corp (ABUS) stock at the moment - Setenews
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Arbutus Biopharma Corp SEC 10-Q Report - TradingView
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):